Clinical Trials Logo

Clinical Trial Summary

To assess the safety and tolerability of SHR-A1912 in patients with B cell lymphoma, to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of SHR-A1912.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05113069
Study type Interventional
Source Shanghai Hengrui Pharmaceutical Co., Ltd.
Contact Weiwei Wang
Phone 86-021-23511999
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date December 6, 2021
Completion date June 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Withdrawn NCT02547948 - CD19-targeting CAR T Cells for B Cell Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03258047 - Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma Phase 2
Recruiting NCT03478514 - Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma Phase 2
Active, not recruiting NCT03307746 - A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma Phase 1/Phase 2
Terminated NCT03670888 - A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients Phase 1
Recruiting NCT04008251 - Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies Phase 1
Recruiting NCT04637763 - CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma Phase 1
Recruiting NCT04782193 - a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma Phase 1/Phase 2
Recruiting NCT03146533 - CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. Phase 1/Phase 2
Recruiting NCT04036019 - A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy Phase 1
Recruiting NCT03366324 - Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies Phase 1/Phase 2
Recruiting NCT03929107 - Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma. Phase 2
Recruiting NCT04289220 - Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia Phase 1
Recruiting NCT03383952 - A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia Phase 1
Completed NCT01593696 - Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma Phase 1
Recruiting NCT03166878 - A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Phase 1/Phase 2
Completed NCT01109069 - Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia Phase 2
Completed NCT01148108 - Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma Phase 2
Completed NCT00741871 - A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies Phase 1